Literature DB >> 22703285

SOXs in human prostate cancer: implication as progression and prognosis factors.

Wei-de Zhong1, Guo-qiang Qin, Qi-shan Dai, Zhao-dong Han, Shan-ming Chen, Xiao-hui Ling, Xin Fu, Chao Cai, Jia-hong Chen, Xi-bin Chen, Zhuo-yuan Lin, Ye-han Deng, Shu-lin Wu, Hui-chan He, Chin-lee Wu.   

Abstract

BACKGROUND: SOX genes play an important role in a number of developmental processes. Potential roles of SOXs have been demonstrated in various neoplastic tissues as tumor suppressors or promoters depending on tumor status and types. The aim of this study was to investigate the involvement of SOXs in the progression and prognosis of human prostate cancer (PCa).
METHODS: The gene expression changes of SOXs in human PCa tissues compared with non-cancerous prostate tissues was detected using gene expression microarray, and confirmed by real-time quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) analysis and immunohositochemistry. The roles of these genes in castration resistance were investigated in LNCaP xenograft model of PCa.
RESULTS: The microarray analysis identified three genes (SOX7, SOX9 and SOX10) of SOX family that were significantly dis-regulated in common among four PCa specimens. Consistent with the results of the microarray, differential mRNA and protein levels of three selected genes were found in PCa tissues by QRT-PCR analysis and immunohistochemistry. Additionally, we found that the immunohistochemical staining scores of SOX7 in PCa tissues with higher serum PSA level (P = 0.02) and metastasis (P = 0.03) were significantly lower than those with lower serum PSA level and without metastasis; the increased SOX9 protein expression was frequently found in PCa tissues with higher Gleason score (P = 0.02) and higher clinical stage (P < 0.0001); the down-regulation of SOX10 tend to be found in PCa tissues with higher serum PSA levels (P = 0.03) and advanced pathological stage (P = 0.01). Moreover, both univariate and multivariate analyses showed that the down-regulation of SOX7 and the up-regulation of SOX9 were independent predictors of shorter biochemical recurrence-free survival. Furthermore, we discovered that SOX7 was significantly down-regulated and SOX9 was significantly up-regulated during the progression to castration resistance.
CONCLUSIONS: Our data offer the convince evidence that the dis-regulation of SOX7, SOX9 and SOX10 may be associated with the aggressive progression of PCa. SOX7 and SOX9 may be potential markers for prognosis in PCa patients. Interestingly, the down-regulation of SOX7 and the up-regulation of SOX9 may be important mechanisms for castration-resistant progression of PCa.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22703285      PMCID: PMC3583167          DOI: 10.1186/1471-2407-12-248

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  28 in total

Review 1.  Sox proteins in melanocyte development and melanoma.

Authors:  Melissa L Harris; Laura L Baxter; Stacie K Loftus; William J Pavan
Journal:  Pigment Cell Melanoma Res       Date:  2010-04-22       Impact factor: 4.693

2.  Sox factors transcriptionally regulate ROBO4 gene expression in developing vasculature in zebrafish.

Authors:  Ganesh V Samant; Marcus O Schupp; Mathias François; Silvia Moleri; Rajendra K Kothinti; Chang Zoon Chun; Indranil Sinha; Suzanna Sellars; Noah Leigh; Kallal Pramanik; Mark A Horswill; Indulekha Remadevi; Keguo Li; George A Wilkinson; Niloofar M Tabatabai; Monica Beltrame; Peter Koopman; Ramani Ramchandran
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

3.  SOX9 is expressed in normal stomach, intestinal metaplasia, and gastric carcinoma in humans.

Authors:  Miho Sashikawa Kimura; Hiroyuki Mutoh; Kentaro Sugano
Journal:  J Gastroenterol       Date:  2011-08-23       Impact factor: 7.527

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer.

Authors:  Rong Hu; Samuel R Denmeade; Jun Luo
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09

6.  Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9.

Authors:  Rolf Drivdahl; Kathy H Haugk; Cynthia C Sprenger; Peter S Nelson; Marie K Tennant; Stephen R Plymate
Journal:  Oncogene       Date:  2004-06-03       Impact factor: 9.867

7.  Sox18 and Sox7 play redundant roles in vascular development.

Authors:  Solei Cermenati; Silvia Moleri; Simona Cimbro; Paola Corti; Luca Del Giacco; Roberta Amodeo; Elisabetta Dejana; Peter Koopman; Franco Cotelli; Monica Beltrame
Journal:  Blood       Date:  2007-12-19       Impact factor: 22.113

8.  Sox10: a pan-schwannian and melanocytic marker.

Authors:  Daisuke Nonaka; Luis Chiriboga; Brian P Rubin
Journal:  Am J Surg Pathol       Date:  2008-09       Impact factor: 6.394

9.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Authors:  M A Eisenberger; B A Blumenstein; E D Crawford; G Miller; D G McLeod; P J Loehrer; G Wilding; K Sears; D J Culkin; I M Thompson; A J Bueschen; B A Lowe
Journal:  N Engl J Med       Date:  1998-10-08       Impact factor: 91.245

10.  Exportin 4 interacts with Sox9 through the HMG Box and inhibits the DNA binding of Sox9.

Authors:  Megumi Tsuchiya; Hidesato Ogawa; Taiga Suzuki; Noriyuki Sugiyama; Tokuko Haraguchi; Yasushi Hiraoka
Journal:  PLoS One       Date:  2011-10-03       Impact factor: 3.240

View more
  35 in total

1.  Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy.

Authors:  Rachel E Beard; Daniel Abate-Daga; Shannon F Rosati; Zhili Zheng; John R Wunderlich; Steven A Rosenberg; Richard A Morgan
Journal:  Clin Cancer Res       Date:  2013-09-10       Impact factor: 12.531

2.  Promoter hypermethylation of SOX11 correlates with adverse clinicopathological features of human prostate cancer.

Authors:  Apiwat Pugongchai; Andrey Bychkov; Pichet Sampatanukul
Journal:  Int J Exp Pathol       Date:  2018-01-08       Impact factor: 1.925

3.  The regulation of SOX7 and its tumor suppressive role in breast cancer.

Authors:  Daniel B Stovall; Meimei Wan; Lance D Miller; Paul Cao; Dejan Maglic; Qiang Zhang; Martha R Stampfer; Wennuan Liu; Jianfeng Xu; Guangchao Sui
Journal:  Am J Pathol       Date:  2013-09-05       Impact factor: 4.307

4.  Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7.

Authors:  Yongzheng Bao; Bin Chen; Qiang Wu; Konghe Hu; Xinhua Xi; Wengang Zhu; Xueren Zhong; Jianting Chen
Journal:  Clin Exp Med       Date:  2015-10-29       Impact factor: 3.984

Review 5.  SOX4: The unappreciated oncogene.

Authors:  Carlos S Moreno
Journal:  Semin Cancer Biol       Date:  2019-08-21       Impact factor: 15.707

Review 6.  SOX7: from a developmental regulator to an emerging tumor suppressor.

Authors:  Daniel B Stovall; Paul Cao; Guangchao Sui
Journal:  Histol Histopathol       Date:  2013-11-29       Impact factor: 2.303

7.  Sox10 expression in ovarian epithelial tumors is associated with poor overall survival.

Authors:  Ah-Young Kwon; Ilyeong Heo; Hye Jin Lee; Gwangil Kim; Haeyoun Kang; Jin-Hyung Heo; Tae Hoen Kim; Hee Jung An
Journal:  Virchows Arch       Date:  2016-03-07       Impact factor: 4.064

8.  Clinicopathological evaluation of Sox10 expression in diffuse-type gastric adenocarcinoma.

Authors:  Marin Kato; Hiroshi Nishihara; Hideyuki Hayashi; Taichi Kimura; Yusuke Ishida; Lei Wang; Masumi Tsuda; Mishie Ann Tanino; Shinya Tanaka
Journal:  Med Oncol       Date:  2016-12-10       Impact factor: 3.064

9.  Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinoma.

Authors:  Aparna Harbhajanka; Satyapal Chahar; Kristy Miskimen; Paula Silverman; Lyndsay Harris; Nicole Williams; Vinay Varadan; Hannah Gilmore
Journal:  Hum Pathol       Date:  2018-06-09       Impact factor: 3.466

10.  Expression of SOX9 Is Related to Prognosis in Patients with Oesophageal Squamous Cell Carcinoma.

Authors:  Naotomo Higo; Hiroshi Okumura; Yasuto Uchikado; Itaru Omoto; Ken Sasaki; Yoshiaki Kita; Desaki Ryosuke; Masahiro Noda; Tetsuhiro Owaki; Sumiya Ishigami; Shoji Natsugoe
Journal:  In Vivo       Date:  2018 Jul-Aug       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.